The iShares S&P Mid-Cap 400 Value ETF (IJJ), currently priced near $122.04, exhibits an implied analyst target price of $140.30, suggesting a 14.96% upside based on the weighted average of its underlying holdings' analyst targets. Key constituents, including Haemonetics Corp. (HAE), Jones Lang LaSalle Inc (JLL), and MKS Inc. (MKSI), show even higher individual analyst-projected upsides of 25.75%, 23.82%, and 18.25% respectively, indicating significant potential value within the ETF's portfolio, though the article prompts further investor diligence on the justification of these targets.
An analysis of the iShares S&P Mid-Cap 400 Value ETF (IJJ) reveals a notable valuation gap based on aggregate analyst price targets. With a recent trading price near $122.04, the ETF's weighted average implied analyst target price is $140.30, suggesting a potential upside of 14.96%. This potential is largely driven by significant upside projected for key individual holdings. Specifically, Haemonetics Corp. (HAE) has a 25.75% upside to its average target of $92.30, Jones Lang LaSalle Inc (JLL) shows a 23.82% upside to its $302.75 target, and MKS Inc. (MKSI) has an 18.25% upside to its $116.67 target. While these figures point to a potentially undervalued ETF, the analysis also raises a critical question regarding the validity and timeliness of these analyst targets, suggesting they could either reflect genuine future optimism or be a precursor to downgrades if not supported by current fundamentals. Therefore, the data presents a compelling but unconfirmed value thesis that requires further diligence.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.30
Ticker Sentiment
